Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access will find a wealth of contextualized life science insight ready to be viewed in the FENIX Marketplace.
Welcome to FENIX Syndicated Services. If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucagon, Glucose Monitoring, Other Jul 28 | 2023Lilly Completes Tirzepatide Obesity Trials; Teladoc, Viking, and Roche Q2 ‘23 EarningsPurchase Blast
$599
Posted in: GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, SGLT2i Jul 25 | 2023Wegovy Label Update; Jardiance Receives EMPA-KIDNEY Approval in EU; Glucotrack Announces Positive Implantable CGM Data; Thane Wettig Succeeds Enrique Conterno as Fibrogen CEOPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Other Jul 24 | 2023Biocon Receives Even More Form 483 Observations; Roche and Alnylam Partner for Hypertension RNAi; Dario Issues Preliminary Q2 ’23 Results and Business UpdatePurchase Blast
$599
Posted in: Basal Insulin, Glucose Monitoring, Insulin Delivery, Other Jul 21 | 2023Abbott Q2 ’23 Earnings; Merck Initiates Ph3 Oral PCSK9i Program; Pfizer Partners with Riparian for CV Development; Amarin Corporate Updates; J&J Q2 ’23 EarningsPurchase Blast
$599
Posted in: Other Jul 18 | 2023Novartis Discontinues Ph2 Obesity Asset; Novartis Q2 ‘23 Earnings; Akebia to Resubmit Vadadustat NDAPurchase Blast
$599
Posted in: Basal Insulin, Dual/triple agonist, GLP-1RA, Other, SGLT2i Jul 17 | 2023Novo and Eleven Therapeutics Collaborate for Nucleic Acid Therapeutics; July CHMP Agenda; Madrigal Completes Resmetirom NDA Submission; Capital Health Partners with Virta Health for Rx Reverse LaunchPurchase Blast
$599
Posted in: GLP-1RA, Glucose Monitoring, Other, SGLT2i Jul 14 | 2023Lilly to Acquire Versanis Bio; Brenzavvy Available by Prescription at Mark Cuban Cost Plus Drug Company; Abbott Initiates Libre 3 trial in T2DM and Basal Therapy; Nemaura FY ‘22 Earnings UpdatePurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Glucose Monitoring, Insulin Delivery, Other Jul 12 | 2023Tandem Mobi Receives FDA Clearance; Better Therapeutics’s AspyreRx Receives FDA Authorization for T2DMPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other Jul 12 | 2023FENIX Analysis: Thoughts on a Potential Zealand AcquisitionPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA Jul 11 | 2023Novo’s GLP-1RA Drugs Under EMA Review; Novartis’s Entresto Patent Ruled Invalid; FDA Approves Expanded Indication for Leqvio; Tonix Initiates Ph2 Intranasal TNX-1900 Study for Pediatric ObesityPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery Jul 06 | 2023Lilly Initiates Three New Ph3 Retatrutide Obesity Trials; Zealand Ph1 Amylin Analog Results; Zealand Dasiglucagon CHI NDA Submitted; Sanofi Signs M1Pram Exclusivity Agreement with Adocia; Dexcom G7 Approved in CanadaPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, Other Jun 29 | 2023Lilly to Acquire Sigilon Therapeutics; FDA Approves First Beta Cell Replacement Therapy for T1DMPurchase Blast
$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Glucagon, Glucose Monitoring, Insulin Delivery Jun 29 | 2023NICE Requests Additional Tirzepatide T2DM Data; Insulet Initiates Omnipod 5 + Libre 2 Study; Esperion Files CLEAR Outcomes in EU; Nemaura Expands proBEAT Pilot; NeuroBo and Terns Announce Preclinical Obesity DataPurchase Blast
$599
Posted in: Basal Insulin, Dual/triple agonist, GLP-1RA, Glucagon, Glucose Monitoring, Insulin Delivery Jun 27 | 2023Lilly Poised to Own the Obesity Market; ADA 2023 Key Press Releases (June 26)Purchase Blast
$599
Posted in: Basal Insulin, GLP-1RA, Other Jun 26 | 2023STEP HFpEF Topline Results; Novo ADA 2023 Investor EventPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA Jun 26 | 2023FENIX Analysis: Breaking Through Novo and Lilly's Obesity DuopolyPurchase Blast
$599
Posted in: Glucose Monitoring, Insulin Delivery Jun 26 | 2023Medtronic Admits It Can’t Achieve iCGM Designation?; 2023 ADA Investor EventPurchase Blast$599
Posted in: Basal Insulin, Bolus Insulin, Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, SGLT2i Jun 25 | 2023ADA 2023 Key Press Releases (June 24)Purchase Blast